Clinical Study
A Pilot Study of Immune Activation and Rifampin Absorption in HIV-Infected Patients without Tuberculosis Infection: A Short Report
Table 1
Immune activation, intestinal assays, and rifampin PK measures.
| Characteristic | Study participant ID | Median value | 101 | 102 | 103 | 104 | 105 | 106 |
| Demographics | | | | | | | | Age (years) | 27 | 25 | 27 | 22 | 33 | 29 | 27 | Weight (kg) | 90 | 65 | 117 | 62 | 90 | 84 | 87 | Sex | F | M | M | M | M | M | — | Immunologic measures | | | | | | | | CD4+ T cells (per uL) | 1573 | 367 | 416 | 724 | 626 | 843 | 675 | sCD14 (ng/mL) | 2412 | 1260 | 1438 | 1435 | 954 | 1243 | 1347.5 | %CD38+ | | | 0 | 0.2 | 0.3 | 0.3 | 0.3 | %HLA-DR+ | | | 21.7 | 9.6 | 16.2 | 28.7 | 19.0 | %CD57+ | | | 7.5 | 2.1 | 0.7 | 10.8 | 4.8 | %CD38+ | | | 1.6 | 0.5 | 1.8 | 4.7 | 1.7 | %HLA-DR+ | | | 73.1 | 27.1 | 81.7 | 73.0 | 73.1 | %CD57+ | | | 37.2 | 11.3 | 16.1 | 5.8 | 13.7 | Intestinal assays | | | | | | | | D-Xylose excretion in urine (g, normal > 4.4 g) | 4.6 | 4.4 | 4.4 | 3.3 | 5.0 | 5.7 | 4.5 g | Lactulose/mannitol ratio | 0.09 | 0.11 | 0.08 | 0.04 | 0.05 | 0.06 | 0.07 | Rifampin PK measures | | | | | | | | (mghr/L) | 28.1 | 43.1 | 21.2 | 57.6 | 46.6 | 42.4 | 42.8 | (mg/L) | 7.8 | 11.6 | 5.3 | 12.5 | 12.5 | 8.7 | 10.1 | (hours) | 4 | 1.5 | 2.5 | 1.5 | 1 | 1 | 1.5 | Clearance (L/hr) | 10.3 | 7.2 | 15.9 | 7.6 | 8.1 | 7.8 | 8.0 | Volume of distribution (L) | 76.9 | 51.7 | 113.2 | 48.0 | 48.0 | 69.0 | 60.4 |
|
|
Insufficient number of PBMCs for flow cytometry.
|